JP2023507799A - 組み合わせ - Google Patents

組み合わせ Download PDF

Info

Publication number
JP2023507799A
JP2023507799A JP2022538229A JP2022538229A JP2023507799A JP 2023507799 A JP2023507799 A JP 2023507799A JP 2022538229 A JP2022538229 A JP 2022538229A JP 2022538229 A JP2022538229 A JP 2022538229A JP 2023507799 A JP2023507799 A JP 2023507799A
Authority
JP
Japan
Prior art keywords
cancer
optionally substituted
compound
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507799A5 (cg-RX-API-DMAC7.html
Inventor
アブディ サマター,アフメド
マ,ジアンフィ
リ,ジアリ
キンファ ファン,ピーター
ガジャナン ヘグデ,サイー
デュアン バンカー,ケビン
ドネイト,フェルナンド
Original Assignee
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー filed Critical リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Publication of JP2023507799A publication Critical patent/JP2023507799A/ja
Publication of JP2023507799A5 publication Critical patent/JP2023507799A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
JP2022538229A 2019-12-20 2020-12-16 組み合わせ Pending JP2023507799A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962952042P 2019-12-20 2019-12-20
US62/952,042 2019-12-20
US202063009754P 2020-04-14 2020-04-14
US63/009,754 2020-04-14
PCT/US2020/065411 WO2021127046A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (2)

Publication Number Publication Date
JP2023507799A true JP2023507799A (ja) 2023-02-27
JP2023507799A5 JP2023507799A5 (cg-RX-API-DMAC7.html) 2023-12-25

Family

ID=76478099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538229A Pending JP2023507799A (ja) 2019-12-20 2020-12-16 組み合わせ

Country Status (12)

Country Link
US (1) US20230042653A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069224A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023507799A (cg-RX-API-DMAC7.html)
KR (1) KR20220119428A (cg-RX-API-DMAC7.html)
CN (1) CN115103673A (cg-RX-API-DMAC7.html)
AU (1) AU2020408698A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012286A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165477A1 (cg-RX-API-DMAC7.html)
IL (1) IL294084A (cg-RX-API-DMAC7.html)
MX (1) MX2022007624A (cg-RX-API-DMAC7.html)
TW (1) TW202135810A (cg-RX-API-DMAC7.html)
WO (1) WO2021127046A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515026A (ja) * 2016-04-01 2019-06-06 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Msd株式会社 Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
CA2706946A1 (en) * 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
HRP20140821T1 (hr) * 2009-09-15 2014-10-10 Merck Sharp & Dohme Corp. Priprema kristalnih hemihidratnih oblika dihidropirazolopirimidinona
SMT201700595T1 (it) * 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
AU2016344040B2 (en) * 2015-11-01 2020-12-10 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
US11932650B2 (en) * 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
EP3712150B1 (en) * 2017-11-01 2024-06-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as wee1 inhibitor and applications thereof
JP2022543832A (ja) * 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515026A (ja) * 2016-04-01 2019-06-06 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GEENEN JJJ, ET AL.: "Molecular Pathways: Targeting the Protein KinaseWee1 in Cancer", CLINICAL CANCER RESEARCH, vol. vol. 23(16), JPN6024050235, 2017, pages 4540 - 4544, ISSN: 0005608806 *

Also Published As

Publication number Publication date
BR112022012286A2 (pt) 2022-08-30
EP4069224A4 (en) 2023-12-20
US20230042653A1 (en) 2023-02-09
MX2022007624A (es) 2022-08-16
CA3165477A1 (en) 2021-06-24
TW202135810A (zh) 2021-10-01
CN115103673A (zh) 2022-09-23
IL294084A (en) 2022-08-01
KR20220119428A (ko) 2022-08-29
AU2020408698A1 (en) 2022-07-14
EP4069224A1 (en) 2022-10-12
WO2021127046A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
JP2023508325A (ja) 組み合わせ
JP7794448B2 (ja) 組み合わせ
JP7750526B2 (ja) 組み合わせ
JP2023507797A (ja) 組み合わせ
KR20230010729A (ko) 단독 요법 및 병용 요법
US20230042653A1 (en) Combinations
WO2021127042A1 (en) Combinations
RU2845443C1 (ru) Комбинации
JP2023508324A (ja) 組み合わせ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250603